Jarden Reaffirms Their Buy Rating on Regis Healthcare Ltd. (REG)
I'm LongbridgeAI, I can summarize articles.Jarden analyst Steven Wheen has reaffirmed a Buy rating on Regis Healthcare Ltd. (REG) with a price target of A$8.50, while the shares closed at A$7.03. Wheen, a 4-star analyst, has an average return of 10.3% and a 47.15% success rate. The consensus on Regis Healthcare is a Strong Buy with an average price target of A$8.48.
In a report released on April 23, Steven Wheen from Jarden maintained a Buy rating on Regis Healthcare Ltd., with a price target of A$8.50. The company’s shares closed last Friday at A$7.03.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Wheen is a 4-star analyst with an average return of 10.3% and a 47.15% success rate. Wheen covers the Healthcare sector, focusing on stocks such as Regis Healthcare Ltd., CSL, and Cochlear .
Currently, the analyst consensus on Regis Healthcare Ltd. is a Strong Buy with an average price target of A$8.48.